|1.||Atici, Aytug: 1 article (04/2007)|
|2.||Taskinlar, Hakan: 1 article (04/2007)|
|3.||Polat, Ayse: 1 article (04/2007)|
|4.||Bozlu, Gulcin: 1 article (04/2007)|
|5.||Turhan, Ali Haydar: 1 article (04/2007)|
|6.||Nayci, Ali: 1 article (04/2007)|
|7.||Okuyaz, Cetin: 1 article (04/2007)|
08/01/1997 - "ABT-491, a highly potent and selective PAF antagonist, inhibits nasal vascular permeability associated with experimental allergic rhinitis in brown Norway rats."
01/01/1998 - "The role of platelet-activating factor (PAF) and the efficacy of ABT-491, a highly potent and selective PAF antagonist, in experimental allergic rhinitis."
01/01/1998 - "These results suggest a therapeutic utility for ABT-491, perhaps in combination with other anti-inflammatory agents, in the treatment of allergic rhinitis."
|2.||Hypotension (Low Blood Pressure)
04/23/1997 - "ABT-491 administered orally was also effective in inhibiting lipopolysaccharide-induced hypotension (ED50 = 0.04 mg/kg), gastrointestinal damage (0.05 mg/kg, 79% inhibition), and lethality (1 mg/kg, 85% vs. 57% survival). "
04/23/1997 - "Administration of ABT-491 in vivo leads to potent inhibition of PAF-induced inflammatory responses (increased vascular permeability, hypotension, and edema) and PAF-induced lethality. "
04/27/2007 - "Administration of ABT-491 either before or after hypoxia resulted in significant reduction of the numbers of apoptotic cells in both hemispheres, when compared to saline treatment group. "
04/27/2007 - "These results suggested that ABT-491, a highly potent and selective PAF antagonist, administration either before or after hypoxia reduces apoptosis and we propose that ABT-491 may be a novel approach in the treatment of HIBI."
04/27/2007 - "They were treated with ABT-491 or saline either immediately before or after hypoxia. "
|1.||Platelet Activating Factor
|2.||Anti-Inflammatory Agents (Anti-Inflammatories)